Broach Lifecare (Maple) Hospital IPO Review

At Broach Lifecare (Maple) Hospital, take immense pride in being at the forefront of healthcare, with a dedicated focus on cardiac ailments. Their state-of-the-art facility boasts an ultra-modern cathlab, a testament to their commitment to providing the highest quality care to their patients.
 
The Company is led by the promoter, Chairman and Managing Director, Dr. Jaykumar Narendra Vyas, who has been associated with the Company since inception and has over 10 years of experience in the field of medicine and healthcare, and the Executive Director, Dr. Shachi Vyas who has more than 8 years of experience in the healthcare sector and is currently responsible for the overall management of the Company.

Financially, Broach Lifecare Hospital revenue is ₹260.58 Lakhs in FY24. Similarly, EBITDA is at ₹102.61 Lakhs in FY24. The PAT is at ₹69.76 Lakhs in FY24. This indicates a steady financial performance.

For the Broach Lifecare Hospital IPO, the company is issuing shares at a pre-issue EPS of ₹1.56 and a post-issue EPS of ₹1.14. The pre-issue P/E ratio is 16.02x, while the post-issue P/E ratio is 21.92x against the industry P/E ratio of 14.92x. The company's ROCE for FY24 is 17.09% and ROE for FY24 is 12.76%. These metrics suggest that the IPO is fairly priced.

The Grey Market Premium (GMP) of Broach Lifecare Hospital indicates potential listing gains of 10% - 15%. Given the company's financial performance and the valuation of the IPO, we recommend Investors to Avoid the Broach Lifecare Hospital Limited IPO for Listing gain or long term investment purposes.